Pulmonary Circulation 2020; 10(1) 1-7
DOI: 10.1177/2045894019876545
Date received: 10 June 2019; accepted: 12 August 2019
ãThe Author(s) 2020
Hemodynamic and clinical effects of selexipag
in children with pulmonary hypertension
Author
Abraham Rothman, MD, Gabriel Cruz, William N. Evans, MD, Humberto
Restrepo, MD, MPH
Source
Abraham Rothman,
Children’s Heart Center Nevada, 3006 S. Maryland Pkwy,
Ste 690, Las
Vegas NV 89109, USA.
Email: arothman@childrensheartcenter.com
Abstract
Selexipag
is an oral prostacyclin receptor agonist; it was recently approved for use in
adults with pulmonary arterial hypertension.
The safety and
efficacy of selexipag has not yet been determined in
the pediatric population.We
describe short-term hemodynamic
and clinical data
with selexipag therapy in four pediatric patients
with pulmonary hypertension. We reviewed clinical, echocardiographic,
and hemodynamic
data. One patient was transitioned from subcutaneous treprostinil
to selexipag, and in three patients,
selexipag
was added as a third agent. Drug dosing was attained empirically based on
patient body size. A follow-up catheterization
was performed
12–18 months after initiation of selexipag therapy.
All four patients tolerated selexipag well, without
significant side
effects. One
patient transitioned successfully from subcutaneous treprostinil
to selexipag. None of the four patients had clinical
deterioration. In
three patients who were able to perform a 6-minute walk test, pre and post selexipag distances were 350 and 400,
409 and 390, and
300 and 360 m, respectively. Echocardiograms showed no significant changes.
Catheterization showed a variable
change in
pulmonary vascular resistance (small decrease in three patients and increase in
one patient). Brain natriuretic peptide
levels before and
after selexipag in the four patients were 38 and 49,
33 and 54, 29 and 25, and 12 and 14 pg/mL,
respectively.
Selexipag
use for 16–28 months was safe in four pediatric patients; none of them had
clinical deterioration. Larger number of
patients and
longer follow-up intervals are necessary before further recommendations can be
made.